Ignite Creation Date:
2024-05-05 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00408018
Status:
TERMINATED
Last Update Posted:
2009-01-01
First Post:
2006-12-04
Brief Title:
Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Sponsor:
Piramal Enterprises Limited
Organization:
Piramal Enterprises Limited
Study Overview
Official Title:
An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms
Status:
TERMINATED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The decision to terminate this study after 202 mgm2 cohort was taken as MTD achieved in other study at 185 mgm2
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
P276-00 is a molecule derived from Rohitukine which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitorThe inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development It therefore has the potential for being efficacious with lesser side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None